Das Bild zeigt eine Ärztin am Schreibtisch im Gespräch mit einer Patientin.

Tumor der Bauchspeicheldrüse | ICD10: C25

Sie befinden sich hier:


Studien offen zur Rekrutierung

ALPACA-Studie_AIO-PAK-0114

136 KB  

First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine (ALPACA)

ARMO ARTIST-1

96 KB  

Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Meta Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen

CANFOUR-Studie

37 KB  

Open-Label-Studie, Dosiseskalation gefolgt von Dosisexpansion, Sicherheits- und Tolerierbarkeitsstudie von CAN04, einem vollständig humanisierten monoklonalem Antikörper gegen IL1RAP, bei Patienten mit soliden malignen Tumoren.

CONKO-007 Studie

57 KB  

CONKO-007: Randomisierte Phase-III-Studie zum Stellenwert einer Radiochemotherapie nach Induktionschemotherapie beim lokal begrenzten, inoperablen Pankreaskarzinom.

CONKO-020

Assessment of the nutrial status changes over the course of disease Prognostic value of IL6 in patient with cancer cachexia

Jannsen CASSINI

144 KB  

Efficacy and Safety of Rivaroxaban Prophylaxis Compared With Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism

Lilly I5B-MC-JGDP

A Phase 1b (Open-Label) / Phase 2 (Randomized Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer

Morpheus WO39608

59 KB  

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

NEOLAP AIO-PAK-0113

159 KB  

Prospective Randomized Multicenter Phase II Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer

Neonax_AIO-PAK-0313

159 KB  

Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer. A phase II study of the AIO Pancreatic Cancer Group.